43 results about "Proteinuria" patented technology

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The invention discloses a walnut-derived xanthine oxidase inhibitory peptide and application thereof, and belongs to the technical field of bioactive peptide biology. The amino acid sequence of the xanthine oxidase inhibitory peptide provided by the invention is as shown in SEQ ID No. 1. Through in-vitro activity determination, the IC50 value of the inhibitory peptide is 3.34 mg / mL, and it is proved that the inhibitory peptide has high inhibitory activity on xanthine oxidase. Besides, the inhibitory peptide can reduce the levels of creatinine, urea nitrogen, adenosine deaminase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, regulate the expression of kidney uric acid resorption protein URAT1, uric acid excretion protein GLUT9 and ABCG2, and significantly reduce the generation of uric acid, can be used for inhibiting xanthine oxidase and preventing or improving hyperuricemia, is applied to preparation of drugs for improving hyperuricemia, and has broad application prospects. The medicine takes the active peptide as the only active ingredient or one of the active ingredients, and has a good application prospect.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The embodiment of the present specification provides an antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease, the antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region. Wherein, the heavy chain variable region comprises CDRH1 of an amino acid sequence as shown in SEQ ID NO: 2, CDRH2 of an amino acid sequence as shown in SEQ ID NO: 3 and CDRH of an amino acid sequence as shown in SEQ ID NO: 4. The light chain variable region comprises CDRL1 of an amino acid sequence as shown in SEQ ID NO: 6, CDRL2 of an amino acid sequence of DTS and CDRL3 of an amino acid sequence as shown in SEQ ID NO: 7. The antibody or antigen binding fragment has the characteristics of high purity, high specificity and sensitivity. The embodiment of the present specification also provides related application of the antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease.

Provided is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the IgA nephropathy by means of a liquid biopsy of blood other than a highly invasive kidney biopsy or conventionally used proteinuria or hematuria. The present invention is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the disease in a subject animal, said method comprising the steps of: (a) measuring an IgA nephropathy marker protein contained in an IgA immune complex in a blood sample collected from the subject animal; and (b) determining the likelihood of the onset or the activity of the IgA nephropathy in the test animal on the basis of the amount of the IgA nephropathy marker protein, which is a protein contained in an IgA immune complex, measured in the step (a), the IgA nephropathy marker protein being a protein contained in an IgA immune complex, and the IgA nephropathy marker protein being a protein contained in an IgA immune complex. The content of the IgA immune complex in the group of IgA nephropathy patients is greater than the content of the IgA immune complex in the group of healthy persons.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The present invention relates to novel polymorphic forms of Iptacopan hydrochloride and preparation thereof. The invention also relates to pharmaceutical composition comprising novel polymorphic forms of Iptacopan hydrochloride and their use in the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.

Methods for treating high proteinuria chronic kidney disease and / or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

The present invention provides a device for detecting an analyte in a liquid sample, the device comprising: a test element for testing whether the analyte exists in the liquid sample or the number of the analyte, the analyte being one or more of the following analyte: neopterin; the amino acid sequence is shown in the description, and the amino acid sequence is shown in the description. The invention relates to a preparation method of a graphene oxide-dopamine composite material. The invention also relates to a method for preparing the microalbuminuria. The microalbuminuria is prepared from the microalbuminuria.

The application discloses a method for constructing a rat passive Heymann nephritis model, and belongs to the technical field of biological medicines, and comprises the following steps: injecting a rat with Sheep Anti-Rat Fx1A Serum through a tail vein for multiple times with an interval of 24 hours. The rat PHN model is successfully constructed by twice tail vein injection of the rat with the Sheep Anti-Rat Fx1A Serum, the model rat shows the nephrotic syndrome characterized by a large amount of proteinuria, the disease course is long, the disease condition is not easy to relieve, and the long-term observation requirement can be met. The modeling method is simple and easy to realize, and can provide research help for dynamic observation of kidney damage of the model animal, discussion of the pathogenesis of the PHN and research and development of drug treatment of the human model nephropathy.

The utility model discloses a urine formation dynamic demonstration instrument capable of segmentally demonstrating, which comprises a nephrology main body structure model, a display board bracket, a solution collector, a circulating water pump, an appendage part and a liquid simulation part, the renal unit main body structure model comprises a glomerulus model, a renal capsule model, a renal tubule model, a filter screen, a globular arteriole model, a globular arteriole model, a renal vein model and a capillary model; the filter screen is embedded at the bottom of a sphere of the glomerular model; the glomerulus model, the kidney capsule model, the bulblet arteriole model and the capillary model penetrate through the display board bracket and extend to the corresponding solution collectors; wherein one end of one renal tubule model passes through the display board bracket and extends to the corresponding solution collector, and the other end extends to the corresponding solution collector on the front side of the display board bracket. According to the utility model, not only can the urine formation process be visually demonstrated, but also students can understand the occurrence mechanism of diseases such as proteinuria and hematuria caused by urinary organ abnormity.

The invention discloses a biomarker for detecting renal fibrosis, application and a system, and relates to the technical field of biological medicines. The invention relates to a biomarker for detecting renal fibrosis. The biomarker comprises urinary copper cyanin. Compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin has the following three advantages: 1, compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin is more sensitive to diagnosis of renal interstitial fibrosis and fibrosis severity; secondly, compared with traumatic renal tissue pathologic biopsy, urine is used as a diagnosis medium, so that true noninvasive effect can be realized, and no harm is caused to the body health of a patient; and thirdly, compared with detection means such as iconography, the method for detecting the urinary cupreocyanin marker is lower in cost, more flexible, high in timeliness and easier to popularize.

The traditional Chinese medicine composition disclosed by the invention adopts a method of warming yang and relieving exterior syndrome to achieve the effects of freeing lung and inducing diuresis, tonifying spleen and warming kidney, and strengthening defensive qi and diminishing swelling, and is prepared to be used for treating the immune-related glomerular diseases, especially membranous nephropathy and minimal lesion nephropathy. The traditional Chinese medicine composition is a pure traditional Chinese medicine preparation, clinical observation and in-vivo and in-vitro basic tests show that the prescription can remarkably improve edema, massive proteinuria, hypoproteinemia and the like, meanwhile, compared with the prior art, the traditional Chinese medicine composition has a better effect on symptoms such as stomachache and diarrhea, has an anti-inflammatory effect and does not have obvious side effects in clinical application. The traditional Chinese medicine composition has an excellent effect on patients suffering from membranous nephropathy and minimal lesion nephropathy caused by syndrome differentiation of spleen-kidney yang deficiency, internal rheumatism and water-fluid overflowing.

An example embodiment may involve obtaining, by a computing system, an observation of demographic values of an individual, vital sign values of the individual, and blood test values of the individual: applying, by the computing system, a machine learning model to the observation, wherein the machine learning model was trained with a training data set, wherein the training data set contained observations of corresponding demographic values, vital sign values, blood test values, and either urine albumin-to-creatinine ratio (UACR) values or urine protein-to-creatinine ratio (UPR) values for a plurality of individuals, and wherein the machine learning model is configured to provide predictions of whether further observations are indicative of undiagnosed albuminuria or proteinuria; and providing, by the computing system, a prediction of whether the individual exhibits undiagnosed albuminuria or proteinuria based on the observation.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

This application discloses the application of uridine phosphorylase 1 (UPP1) as an inhibitory target in the preparation of drugs for treating systemic lupus erythematosus (SLE), relating to the field of biomedical technology. This application is the first to discover abnormally elevated UPP1 expression in peripheral blood mononuclear cells of SLE patients, which is positively correlated with disease activity. Validation experiments demonstrate that the specific inhibitor of UPP1, BAU, can effectively inhibit UPP1 enzyme activity. In cell models, it reduces inflammatory factors and type I interferon responses induced by STING pathway activation. In SLE animal models, BAU significantly reduces splenomegaly, proteinuria, and pathological damage to the kidneys and lungs, decreases the proportion of pathogenic immune cells such as M1 macrophages, Th1 cells, and plasma cells in the spleen, and inhibits the deposition of immune complexes in the glomeruli. This invention reveals for the first time the potential of UPP1 as a novel therapeutic target for SLE and provides BAU as a candidate drug for treating SLE and related organ damage, offering a novel strategy for clinical intervention.

The invention discloses a traditional Chinese medicine composition for treating targeted drug related proteinuria, a pharmaceutical preparation and application. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials or extracts thereof: angelica sinensis, radix paeoniae alba, raw astragalus membranaceus, radix pseudostellariae, radix ophiopogonis, schisandra chinensis, raw atractylodes macrocephala koidz and divaricate saposhnikovia roots. The traditional Chinese medicine composition treats the anti-angiogenesis targeted drug related proteinuria through the treatment rules of activating blood and nourishing liver, and invigorating spleen and tonifying kidney, so that the patients can be treated by drugs, and the risk of drug withdrawal of the hepatocellular carcinoma patients due to the anti-angiogenesis targeted drug related proteinuria such as a vascular endothelial growth factor inhibitor is further reduced; the long-term prognosis of hepatocellular carcinoma patients is improved, and the lifetime of the hepatocellular carcinoma patients is prolonged.

The invention discloses a method for constructing a spontaneous systemic lupus erythematosus animal model, which comprises the following steps: knocking out EP300 (E1A Binding Protein P300) in keratinocytes to enable a mouse to spontaneously have systemic lupus erythematosus phenotypes, including local skin unhairing, persistent skin lesion, persistent proteinuria and serum autoantibodies; the systemic lupus erythematosus sample changes such as dermal immune cell infiltration and glomerular IgG deposition exist in histological examination, clinical symptoms of systemic lupus erythematosus are simulated, and an important tool is provided for related research of systemic lupus erythematosus.

The invention discloses a traditional Chinese medicine composition for preventing and treating pregnancy complications as well as a preparation method and application thereof. The composition is composed of medicinal and edible traditional Chinese medicines including radix rehmanniae recen, fructus gardeniae, gastrodia elata, fructus lycii and exocarpium citri rubrum, and mulberry leaves, ramulus uncariae cum uncis and the like can be selectively added. The preparation method comprises the steps of extracting volatile oil by steam distillation, leaching by a solvent, concentrating, mixing and the like, and can be combined with ultrasonic crushing to strengthen extraction. The composition is based on the treatment method of nourishing kidney, containing wood, clearing heat, calming liver, dissolving turbidity and preventing miscarriage in traditional Chinese medicine, has the effects of multi-target synergistic pressure reduction, proteinuria improvement and fetal development promotion aiming at the pathogenesis of yin deficiency and yang hyperactivity in the gestation period, is high in safety and free of fetal toxic and side effects, and is suitable for prevention and treatment of hypertensive diseases in the gestation period such as preeclampsia and the like.

Disclosed are methods for treating high proteinuria chronic kidney disease and / or at least one disease, disorder or condition associated therewith in a patient by using a fixed dose combination of zipotentan and dapagliflozin.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.

The present invention relates to a method of treating a glomerular kidney disease in a human patient in need thereof, comprising administering to the patient an isolated antibody or an antigen binding fragment thereof that binds to soluble urokinase plasminogen activator receptor (suPAR). The present invention also relates to a method of reducing proteinuria associated with a kidney disease in a patient in need thereof, comprising administering to the patient an isolated antibody or an antigen binding fragment thereof that binds to suPAR. The present invention also relates to a method of inhibiting suPAR in a patient in need thereof, having a glomerular kidney disease, with the same isolated antibody or fragment thereof.

The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10 to 20 parts of radix achyranthis bidentatae, 15 to 25 parts of prepared rhizoma polygonati, 15 to 25 parts of lucid ganoderma, 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of cordyceps cicadae, 15 to 25 parts of caulis spatholobi, 10 to 30 parts of fiveleaf gynostemma herb, 15 to 25 parts of thesium chinense, 5 to 15 parts of taxus chinensis, 15 to 25 parts of radix puerariae, 5 to 15 parts of radix notoginseng and 5 to 15 parts of rhizoma curcumae. The traditional Chinese medicine composition disclosed by the invention is applied to medicines for treating diabetic nephropathy, so that the blood sugar of a patient is stable, proteinuria is reduced, the renal function deterioration process is slowed down, and the life quality of the patient is improved.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.

Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.

The application belongs to the field of biological medicine, and provides application of inosine in preparation of a drug for preventing and / or treating preeclampsia. The pathological state of preeclampsia is simulated by subcutaneous injection of a solution of nitroso-L-arginine methyl ester (125 mg / kg). From the 9th day of pregnancy, inosine is administered by gavage once a day (100 mg / kg), until the end of pregnancy. Compared with drugs such as labetalol, magnesium sulfate and other drugs with single treatment effect, the application proves that oral inosine can not only significantly improve hypertension and proteinuria caused by preeclampsia, repair placental function, promote intrauterine growth and development of the fetus, correct the imbalance of vascular and anti-angiogenic factors, but also reduce the damage to the kidneys and brain of pregnant women induced by preeclampsia, and exhibits a more comprehensive treatment effect, thereby providing a new therapeutic drug for preventing or treating preeclampsia.

The invention belongs to the field of biological medicines, and provides application of inosine in preparation of a medicine for preventing and / or treating preeclampsia. According to the invention, the pathological state of preeclampsia is simulated through subcutaneous injection of a nitroso-L-arginine methyl ester solution (125 mg / kg). And from the 9th day of pregnancy, gastro-inosine is irrigated once a day (100mg / kg) until the end of pregnancy. Compared with medicines with a single treatment effect, such as an antihypertensive medicine labeolol and a spasmolysis medicine magnesium sulfate, the invention proves that oral inosine not only can remarkably improve hypertension and proteinuria caused by preeclampsia, repair placenta functions, promote intrauterine growth and development of fetuses and correct imbalance of blood vessels and anti-angiogenesis factors, but also has the effects of preventing and treating the preeclampsia. In addition, kidney and brain injuries, induced by preeclampsia, of pregnant and lying-in women can be relieved, a more comprehensive treatment effect is shown, and a novel treatment medicine is provided for preventing or treating preeclampsia.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

The present application belongs to the technical field of biological medicine, and particularly relates to the use of a secreted lactase-like protein (LCTL) as a diagnostic marker in the preparation of a chronic kidney disease diagnostic kit. The present application first discovers that LCTL exists in a secreted form, first detects the content of secreted LCTL in human serum by using an existing commercial ELISA kit, further research finds that the content of secreted LCTL in serum of patients with chronic kidney disease is significantly lower than that of normal people, and the content of LCTL in serum is significantly related to the degree of kidney function damage and the degree of proteinuria of patients, and therefore the use of secreted LCTL in the preparation of a biomarker for the diagnosis of chronic kidney disease is first proposed. The present application provides a new method for the diagnosis of chronic kidney disease, and has great clinical significance and commercial value.